摘要
Background Angiogenesis is an essential step for tumor development and metastasis.The cell adhesion molecule αvβ3 integrin plays an important role in angiogenesis and is a specific marker of tumor angiogenesis.A novel αvβ3 integrintargeted magnetic resonance （MR） imaging contrast agent utilizing Arg-Gly-Asp （RGD） and ultrasmall superparamagnetic iron oxide particles （USPIO） （referred to as RGD-USPIO） was designed and its uptake by endothelial cells was assessed both in vitro and in vivo to evaluate the angiogenic profile of lung cancer.Methods USPIO were coated with-NH3＋ and conjugated with RGD peptides.Prussian blue staining was performed to evaluate the specific uptake of RGD-USPIO by human umbilical vein endothelial cells （HUVECs）.Targeted uptake and subcellular localization of RGD-USPIO in HUVECs were confirmed by transmission electron microscopy （TEM）.The ability of RGD-USPIO to noninvasively assess αvβ3 integrin positive vessels in lung adenocarcinoma A549 tumor xenografts was evaluated with a 4.7T MR scanner.Immunohistochemistry was used to detect αvβ3 integrin expression and vessel distribution in A549 tumor xenografts.Results HUVECs internalized RGD-USPIO significantly more than plain USPIO.The uptake of RGD-USPIO by HUVECs could be competitively inhibited by addition of free RGD.A significant decrease in T2 signal intensity （SI） was observed at the periphery of A549 tumor xenografts at 30 minutes （P 〈0.05） and 2 hours （P 〈0.01） after RGD-USPIO was injected via the tail vein.Angiogenic blood vessels were mainly distributed in the periphery of tumor xenografts with positive αvβ3 integrin expression.Conclusions RGD-USPIO could specifically label αvβ3 integrin and be taken up by HUVECs.This molecular MR imaging contrast agent can specifically evaluate the angiogenic profile of lung cancer using a 4.7T MR scanner.
Background Angiogenesis is an essential step for tumor development and metastasis.The cell adhesion molecule αvβ3 integrin plays an important role in angiogenesis and is a specific marker of tumor angiogenesis.A novel αvβ3 integrintargeted magnetic resonance （MR） imaging contrast agent utilizing Arg-Gly-Asp （RGD） and ultrasmall superparamagnetic iron oxide particles （USPIO） （referred to as RGD-USPIO） was designed and its uptake by endothelial cells was assessed both in vitro and in vivo to evaluate the angiogenic profile of lung cancer.Methods USPIO were coated with-NH3＋ and conjugated with RGD peptides.Prussian blue staining was performed to evaluate the specific uptake of RGD-USPIO by human umbilical vein endothelial cells （HUVECs）.Targeted uptake and subcellular localization of RGD-USPIO in HUVECs were confirmed by transmission electron microscopy （TEM）.The ability of RGD-USPIO to noninvasively assess αvβ3 integrin positive vessels in lung adenocarcinoma A549 tumor xenografts was evaluated with a 4.7T MR scanner.Immunohistochemistry was used to detect αvβ3 integrin expression and vessel distribution in A549 tumor xenografts.Results HUVECs internalized RGD-USPIO significantly more than plain USPIO.The uptake of RGD-USPIO by HUVECs could be competitively inhibited by addition of free RGD.A significant decrease in T2 signal intensity （SI） was observed at the periphery of A549 tumor xenografts at 30 minutes （P 〈0.05） and 2 hours （P 〈0.01） after RGD-USPIO was injected via the tail vein.Angiogenic blood vessels were mainly distributed in the periphery of tumor xenografts with positive αvβ3 integrin expression.Conclusions RGD-USPIO could specifically label αvβ3 integrin and be taken up by HUVECs.This molecular MR imaging contrast agent can specifically evaluate the angiogenic profile of lung cancer using a 4.7T MR scanner.
